Biology of Blood and Marrow Transplantation · 2014 · 99 citations · 19 references
MedicineHematologyImmunologyCell TherapyStem Cell TransplantationTransplant ImmunologyAllogeneic Stem Cell TransplantationDonor MatchingHematopoietic Stem Cell TransplantationHistocompatibilityMaintenance ImmunosuppressionBone Marrow - Derived CellsCyclophosphamide-based ConditioningGata2 DeficiencyNon-myeloablative ConditioningPeripheral Blood Stem CellsPost-transplant CyclophosphamidePost-transplant ImmunosuppressionUnrelated Donation
We treated 14 patients with GATA2 deficiency using a nonmyeloablative allogeneic hematopoietic stem cell transplantation regimen. Four patients received peripheral blood stem cells from matched related donors (MRD), 4 patients received peripheral blood stem cells from matched unrelated donors (URD), 4 patients received hematopoietic stem cells from umbilical cord blood donors (UCB), and 2 patients received bone marrow cells from haploidentical related donors. MRD and URD recipients received conditioning with 3 days of fludarabine and 200 cGy total body irradiation (TBI). Haploidentical related donor recipients and UCB recipients received cyclophosphamide and 2 additional days of fludarabine along with 200 cGY TBI. MRD, URD, and UCB recipients received tacrolimus and sirolimus for post-transplantation immunosuppression, whereas haploidentical recipients received high-dose cyclophosphamide followed by tacrolimus and mycophenolate mofetil. Eight patients are alive with reconstitution of the severely deficient monocyte, B cell, and natural killer cell populations and reversal of the clinical phenotype at a median follow-up of 3.5 years. Two patients (1 URD recipient and 1 UCB recipient) rejected the donor graft and 1 MRD recipient relapsed with myelodysplastic syndrome after transplantation. We are currently using a high-dose conditioning regimen with busulfan and fludarabine in patients with GATA2 deficiency to achieve more consistent engraftment and eradication of the malignant myeloid clones.
19
International Scoring System for Evaluating Prognosis in Myelodysplastic Syndromes
Peter L. Greenberg, Christopher Cox, Michelle M. LeBeau et al. · Blood · 1997 · 4.5K citations · Full text
Leo Luznik, Paul V. O’Donnell, Heather J. Symons et al. · Biology of Blood and Marrow Transplantation · 2008 · 1.9K citations · Full text
Medicine, Hematology, Oncology +16
Marcie Tomblyn, Tom Chiller, Hermann Einsele et al. · Biology of Blood and Marrow Transplantation · 2009 · 1.8K citations · Full text
Reduced Mortality after Allogeneic Hematopoietic-Cell Transplantation
Ted Gooley, Jason W. Chien, Steven A. Pergam et al. · New England Journal of Medicine · 2010 · 1.5K citations · Full text
Medicine, Hematology, Surgery +17
GATA2 deficiency: a protean disorder of hematopoiesis, lymphatics, and immunity
Michael A. Spinner, Lauren A. Sanchez, Amy P. Hsu et al. · Blood · 2013 · 706 citations · Full text
Life Sciences, Genetics, Immunology +12